GlassScriptPhysician profile
Mary Ann Martinez
NPI 1497778104
$3,434.19
in general payments reported to CMS, 2019-2025
23 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $12.84 · 2021: $1,553 · 2022: $407 · 2023: $188 · 2024: $573 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927 · Education: $95.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.52 |
| Education | $95.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $1,531.60 | 2021-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $293.02 | 2019-2024 | Cabtreo |
| Incyte Corporation | $251.88 | 2022-2024 | Opzelura |
| Almirall LLC | $194.58 | 2021-2024 | Seysara |
| Mayne Pharma Commercial LLC | $192.75 | 2019-2025 | |
| Abbvie INC. | $186.94 | 2023-2025 | |
| Galderma Laboratories, L.P. | $179.71 | 2024 | Aklief, Dysport |
| Pfizer INC. | $98.69 | 2019-2024 | |
| Leo Pharma INC. | $83.43 | 2022-2025 | Anzupgo, Adbry |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Novartis Pharmaceuticals Corporation | $67.48 | 2025 | |
| Sun Pharmaceutical Industries INC. | $49.44 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.48 | 2022 | |
| Amgen INC. | $36.53 | 2022-2025 | Otezla |
| Pierre Fabre Pharmaceuticals, INC. | $26.06 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $20.75 | 2019 | |
| Organon LLC | $19.15 | 2025 | Vtama |
| Allergan, INC. | $19.07 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.40 | 2024 | Dupixent |
| Arcutis Biotherapeutics, INC. | $14.66 | 2023 | |
| Epi Health, LLC | $12.34 | 2022 | |
| Mission Pharmacal Company | $11.24 | 2019 | |
| Glenmark Therapeutics INC. | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ann Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.